Avitar and Pinkerton to collaborate on marketing trials to launch ORALscreen drugs
Avitar Inc plans to collaborate on marketing trials with Pinkerton Inc to develop and launch ORALscreen OSR, the world's first automated analyzer for the detection of drugs of abuse utilizing the ORALscreen system.
The new product is designed to develop and interpret the results of Avitar's current ORALscreen test, and will satisfy the needs of large volume users. ORALscreen OSR will provide capabilities to the customer for recording, reporting and managing the information utilizing various communication channels and storage medium.
``We are pleased to announce our collaboration with Pinkerton on the development of ORALscreen OSR, which we believe will be well received in the marketplace as we combine our technology with Pinkerton's sales and service resources,'' said Peter P. Phildius, Avitar's Chairman and Chief Executive Officer. ``ORALscreen OSR will provide Avitar with the ability to perform drug testing using the ORALscreen, both independent of the analyzer, as well as in cooperation with the system. No other competitor can offer this unique and cost effective design, which will make converting our current customers, who want an automated system, easy and seamless.
Don Weber, Vice President of Pinkerton, Health Services Division, said, ``Based on our current relationship with Avitar, we are confident that this new product will prove to be another breakthrough in this growing marketplace. Pinkerton prides itself on being at the cutting edge of technology in the services we deliver, and this joint project will benefit both companies as we attempt to commercialize this product as soon as possible.''
The ORALscreen OSR analyzer is designed to provide quick and accurate results using the ORALscreen POCT device. The analyzer is a hand-held instrument capable of reading and interpreting of up to 10 different drug classes in 2 minutes or less. The ORALscreen OSR system offers several modes of communication including internet and RS232 ports. The ORALscreen OSR platform has been designed to incorporate future diagnostic applications such as diabetes and fertility POCT tests in oral fluid.